


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450  
Alexandria, VA 22313 on October 19, 2006.

AMENDMENT UNDER 37 CFR  
§1.825(a) THROUGH (c)  
Patent Application  
Docket No. SER-111  
Serial No. 10/582,027

  
\_\_\_\_\_  
Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Maria Dorly Del Curto  
Serial No. : 10/582,027  
Filed : June 8, 2006  
Conf. No. : 1354  
For : Stabilized Interferon Liquid Formulations

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 CFR §1.825(a) THROUGH (c)

Sir:

In response to the Notification to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures received in the above-identified patent application, please amend the subject application as follows, in order to comply with the requirements of 37 CFR §§1.821-1.825: